Open Government Portal
About this information
Open data is defined as structured data that is machine-readable, freely shared, used and built on without restrictions.
The key things to remember about open data are:
- #Availability and access#: the data must be available as a whole and at no more than a reasonable reproduction cost, preferably by downloading over the internet. The data must also be available in a convenient and modifiable form.
- #Re-use and redistribution#: the data must be provided under terms that permit re-use and redistribution including the intermixing with other datasets.
- #Universal participation#: everyone must be able to use, re-use and redistribute. There should be no discrimination against fields of endeavour or against persons or groups. For example, 'non-commercial' restrictions that would prevent 'commercial' use, or restrictions of use for certain purposes (e.g. only in education), are not allowed.
The drug supply chain is highly integrated and interdependent. All stakeholders have important roles to play when it comes to …
Drug shortages are a complex and pressing global issue with serious implications for the health and well-being of Canadians. Sudden …
Notification and communication of drug shortages by drug manufacturers and importers is an essential component of preventing and mitigating shortages. …
Health Canada is responsible for helping the people of Canada maintain and improve their health. This is done, in part, …
Organizations and the provinces/territories continue to make progress in the marketing and reimbursement of edaravone (brand name Radicava). Currently, all …
Health Canada and the U.S. Food and Drug Administration (FDA) are holding joint public consultation meetings on International Council for …
Health Canada is pleased to announce the release of five associated revised draft guidance documents on Post-Notice of Compliance (NOC) …
Drugs are authorized for sale in Canada once they have successfully gone through the drug review process, which includes the …
Health Canada is revising the Guidance Document entitled: The Management of Drug Submissions and Applications (MDSA). This document provides sponsors …
Health Canada is issuing this Notice to clinical trial sponsors to clarify the approach to various types of clinical research …